Navigation Links
Regeneron Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
Date:10/13/2010

NEW YORK, Oct. 13 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today the completion of its previously announced underwritten public offering of 5,500,000 shares of Common Stock, as well as 825,000 additional shares of its Common Stock pursuant to the full exercise of the over-allotment option granted to the underwriter.  The total proceeds of the offering (before estimated offering expenses) were approximately $175.1 million.  Citi acted as the sole book-running manager for the offering.  The shares were offered by Regeneron under the Company's shelf registration statement.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.  Copies of the prospectus supplement and accompanying prospectus related to this offering may be obtained by sending a request to the offices of Citi at Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, NY 11220, telephone number (800) 831-9146.  Alternatively, these documents are available by visiting EDGAR on the SEC website at www.sec.gov.

About Regeneron Pharmaceuticals Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.

Forward-Looking Statements: Regeneron Pharmaceuticals, Inc.This news release includes forward-looking statements about Regeneron and its products, development programs, finances, and business, all of which involve a number of risks and uncertainties. These include, among others, risks and timing associated with preclinical and clinical development of Regeneron's drug candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that are superior to Regeneron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with Astellas, the sanofi-aventis Group and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission (SEC), including its Form 10-K for the year ended December 31, 2009 and Form 10-Q for the quarter ended June 30, 2010. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise, unless required by law.RegeneronMichael Aberman, M.D.

Peter DworkinInvestor Relations

Corporate Communications914.345.7799

914.345.7640michael.aberman@regeneron.com

peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regeneron Increases Size of Public Offering of Common Stock
2. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
3. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
4. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
5. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
6. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
7. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
8. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
9. Regeneron Reports Third Quarter 2009 Financial and Operating Results
10. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
11. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... nearly two decades, New Life Agency has been committed to providing the ... Life Agency announces a powerful three-way partnership designed to deliver substantial savings ... ... http://www.schrafts2.com/ (PRNewsfoto/PharmaCareCard) ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/6/2017)... SAN ANTONIO , Sept. 6, 2017  Robert ... as a Pinnacle Professional Member in recognition of his ... Dr. Szewc serves as a Nephrologist at the practice ... services, emergency medicine, kidney care and hypertension solutions. He ... over 20 years of career experience, as well as ...
(Date:9/5/2017)... -- Sapheneia and Scannerside received FDA 510(k) clearance to ... third-party Vendor neutral CT product that makes it affordable ... current MITA standards. ... specifically designed to provide CT operators, prior to a ... a predefined threshold. Scannerside Dose Check is intended to ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... “Psalms of Humidity”: is a ... mind and move the readers one step closer to God. “Psalms of Humidity” is ... his mistakes that have been made within his life are the very same things ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Monique”: is the story of Monique, whose ... creation of published author, Colleen Crispi, has owned four beauty salons and written a ... in real estate and cooking. , “The doctor’s office was only three blocks ...
(Date:9/19/2017)... Birmingham, Alabama (PRWEB) , ... September 19, 2017 ... ... a customer success story on St. Vincent’s Infusion Services called, “PAPA Healthcare helps ... how St. Vincent’s Infusion Services enhanced service delivery and operations by leveraging PAPA ...
(Date:9/19/2017)... ... September 19, 2017 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... part of its national Swirl: A Wine Tasting Event series on Thursday, October ...
(Date:9/19/2017)... ... September 19, 2017 , ... The American Board ... to watch for the discomforts and hidden dangers of foot fungus, particularly in ... is at risk for developing fungal infections on the feet or toenails, the ...
Breaking Medicine News(10 mins):